Here's Why BioMarin Pharmaceutical ( BMRN ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Peering Into BioMarin Pharmaceutical's Recent Short Interest - BioMarin Pharmaceutical ( NASDAQ:BMRN )
BioMarin Pharmaceutical's BMRN short interest as a percent of float has risen 19.85% since its last report. According to exchange reported data, there are now 5.96 million shares sold short, which is 3.14% of all regular shares that are available for trading.
Why BioMarin Pharmaceutical ( BMRN ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why BioMarin Pharmaceutical ( BMRN ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock?
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
PTC Therapeutics To Challenge BioMarin's Metabolic Disorder Treatment - BioMarin Pharmaceutical ( NASDAQ:BMRN )
45% of adolescents on Palynziq cut blood phenylalanine by 50% or more from baseline. The study enrolled 55 teens; Palynziq showed better results than diet alone after 72 weeks. Get the strategy to turn September's volatility into 10x trades → On Saturday, BioMarin Pharmaceutical Inc.
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Bullish ( NYSE:BLSH ) , BioMarin Pharmaceutical ( NASDAQ:BMRN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Joseph Vafi initiated coverage on Bullish BLSH with a Buy rating and ...
BioMarin ( BMRN ) Down 4.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why BioMarin Pharmaceutical ( BMRN ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
What's Driving the Market Sentiment Around BioMarin Pharmaceutical? - BioMarin Pharmaceutical ( NASDAQ:BMRN )
BioMarin Pharmaceutical's BMRN short percent of float has fallen 3.68% since its last report. The company recently reported that it has 4.96 million shares sold short, which is 2.62% of all regular shares that are available for trading.
Here's Why BioMarin Pharmaceutical ( BMRN ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Pharmaceutical ( BMRN ) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical ( BMRN ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is BioMarin Pharmaceutical Gaining or Losing Market Support? - BioMarin Pharmaceutical ( NASDAQ:BMRN )
BioMarin Pharmaceutical's BMRN short percent of float has fallen 15.79% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 2.72% of all regular shares that are available for trading.
Why BioMarin Pharmaceutical ( BMRN ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - BioMarin Pharmaceutical ( NASDAQ:BMRN )
BioMarin Q2 earnings rose 50% to $1.44 per share, topping estimates of $0.85. 2025 EPS guidance raised to $4.40-$4.55 vs. consensus of $3.45. The market's back, and these 3 income stocks are thriving. See them here→ On Tuesday, Biomarin Pharmaceutical Inc.
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
BioMarin ( BMRN ) Q2 Revenue Jumps 16%
BioMarin Pharmaceutical ( NASDAQ:BMRN ) , a biotechnology company focused on therapies for rare genetic conditions, reported results for Q2 2025 on August 4, 2025. GAAP revenue was $825 million, far above expectations of $761.66 million, and non-GAAP Earnings Per Share ( EPS ) of $1.44 compared ...
BioMarin ( BMRN ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, Aug. 4, 2025 at 8:30 p.m. ETPresident and Chief Executive Officer - Alexander HardyContinue reading ...
BioMarin Pharmaceutical ( BMRN ) Q2 Earnings and Revenues Surpass Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of +39.81% and +7.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Is PTC Therapeutics Stock Trading Higher Today? - PTC Therapeutics ( NASDAQ:PTCT )
Sephience is approved for sepiapterin-responsive PKU in patients 1 month and older. Wholesale cost is $40,000 a month; U.S. launch starts in August, targeting 1,200 prescribers. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. The U.S.
ANI Pharmaceuticals ( ANIP ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical ( BMRN ) Reports Next Week: Wall Street Expects Earnings Growth
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Escalating Medical Costs Dampen Centene's Q2 Earnings?
CNC's Q2 earnings are likely to have felt the pinch as rising medical costs pressure margins despite higher premium revenues.
What Does the Market Think About BioMarin Pharmaceutical? - BioMarin Pharmaceutical ( NASDAQ:BMRN )
BioMarin Pharmaceutical's BMRN short percent of float has risen 47.64% since its last report. The company recently reported that it has 6.52 million shares sold short, which is 3.44% of all regular shares that are available for trading.
Looking for a Growth Stock? 3 Reasons Why BioMarin ( BMRN ) is a Solid Choice
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think BioMarin ( BMRN ) Could Surge 70.77%: Read This Before Placing a Bet
The consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money
Three magnificent businesses with well-defined catalysts can deliver triple-digit returns amid a historically pricey stock market.
Here's Why BioMarin Pharmaceutical ( BMRN ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical ( BMRN ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will BioMarin ( BMRN ) Beat Estimates Again in Its Next Earnings Report?
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
BOSTON, June 20, 2025 ( GLOBE NEWSWIRE ) -- Inozyme Pharma, Inc. ( Nasdaq: INZY ) today announced that it has postponed its 2025 Annual Meeting of Stockholders ( the "Annual Meeting" ) , which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition ( the ...
Jim Cramer: All Aboard Union Pacific, 'Tired' Of Orphan Drugs - GitLab ( NASDAQ:GTLB ) , BioMarin Pharmaceutical ( NASDAQ:BMRN )
"I was prepared for disappointment and I got it," Cramer on GitLab. "I think it's a really good stock to own," Cramer on Union Pacific. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
A volatile stock market represents an ideal opportunity for long-term investors to pounce.
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders - Inozyme Pharma ( NASDAQ:INZY ) , Protagenic Therapeutics ( NASDAQ:PTIX )
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inozyme Pharma, Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. ( Nasdaq - INZY ) , TXNM Energy, Inc. ( NYSE - TXNM ) , Servotronics, Inc. ( NYSE American - SVT ) , Protagenic Therapeutics, Inc. ( Nasdaq - PTIX )
BALA CYNWYD, Pa., May 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. ( Nasdaq - INZY ) , TXNM Energy, Inc. ( NYSE - TXNM ) , Servotronics, Inc. ( NYSE American - SVT ) , Protagenic Therapeutics, Inc. ( Nasdaq - PTIX )
BALA CYNWYD, Pa., May 19, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders - Inozyme Pharma ( NASDAQ:INZY ) , Charter Communications ( NASDAQ:CHTR )
NEW YORK, May 18, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SpringWorks Therapeutics, Inc.
A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings - Biomarin Pharmaceutical ( NASDAQ:BMRN )
Looking into the current session, Biomarin Pharmaceutical Inc. BMRN shares are trading at $64.59, after a 3.00% increase. Moreover, over the past month, the stock spiked by 3.79%, but in the past year, decreased by 23.82%.
BioMarin's First-Quarter Earnings & Sales Beat Estimates
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
BioMarin Pharmaceutical ( BMRN ) Beats Q1 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 20.21% and 1.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for BioMarin Stock Options
Investors need to pay close attention to BMRN stock based on the movements in the options market lately.
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Bristol Myers Squibb ( BMY ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical ( BMRN ) Earnings Expected to Grow: What to Know Ahead of Q1 Release
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Legend Biotech ( LEGN ) Moves 5.1% Higher: Will This Strength Last?
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
